AMNEAL PHARMACEUTICALS, INC. Increase (Decrease) in Due to Related Parties
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Increase (Decrease) in Due to Related Parties of -$49.63 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueToRelatedParties · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in due to related parties for the quarter ending 2026-06-30 was -$8.53M, a 232.93% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in due to related parties for the quarter ending 2026-03-31 was -$41.10M.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in due to related parties for the quarter ending 2025-12-31 was -$2.18M, a 106.38% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in due to related parties for the quarter ending 2025-09-30 was -$2.19M, a 120.39% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in due to related parties for fiscal 2025 was $931.00K, a 98.29% decline from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in due to related parties for fiscal 2024 was $54.44M, a 453.88% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in due to related parties for fiscal 2023 was $9.83M, a 374.37% increase from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in due to related parties for fiscal 2022 was $2.07M.
| Period end | Increase (Decrease) in Due to Related Parties 3 month | Increase (Decrease) in Due to Related Parties 6 month | Increase (Decrease) in Due to Related Parties 9 month | Increase (Decrease) in Due to Related Parties 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$49.63M 10-Q · filed 2026-08-06 | -$51.81M derived: sum of 3 quarters · filed 2026-08-06 | -$53.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$41.10M 10-Q · filed 2026-05-07 | -$43.28M derived: sum of 2 quarters · filed 2026-05-07 | -$45.46M derived: sum of 3 quarters · filed 2026-05-07 | -$39.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$4.36M derived: sum of 2 quarters · filed 2026-02-27 | $2.06M derived: sum of 3 quarters · filed 2026-08-06 | $931.00K 10-K · filed 2026-02-27 |
| 2025-09-30 | -$2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.23M derived: sum of 2 quarters · filed 2026-08-06 | $3.11M 10-Q · filed 2025-11-06 | $37.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.29M 10-Q · filed 2026-08-06 | $39.40M derived: sum of 3 quarters · filed 2026-08-06 | $50.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.12M 10-Q · filed 2026-05-07 | $32.98M derived: sum of 2 quarters · filed 2026-05-07 | $43.70M derived: sum of 3 quarters · filed 2026-05-07 | $47.82M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $34.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $44.82M derived: sum of 2 quarters · filed 2026-02-27 | $48.95M derived: sum of 3 quarters · filed 2026-02-27 | $54.44M 10-K · filed 2026-02-27 |
| 2024-09-30 | $10.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $14.84M derived: sum of 2 quarters · filed 2025-11-06 | $20.34M 10-Q · filed 2025-11-06 | $26.01M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $4.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $9.62M 10-Q · filed 2025-08-07 | $15.29M derived: sum of 3 quarters · filed 2026-02-27 | $16.54M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $5.50M 10-Q · filed 2025-05-07 | $11.17M derived: sum of 2 quarters · filed 2026-02-27 | $12.41M derived: sum of 3 quarters · filed 2026-02-27 | $13.65M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $6.92M derived: sum of 2 quarters · filed 2026-02-27 | $8.16M derived: sum of 3 quarters · filed 2026-02-27 | $9.83M 10-K · filed 2026-02-27 |
| 2023-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.48M derived: sum of 2 quarters · filed 2024-11-12 | $4.16M 10-Q · filed 2024-11-12 | $3.75M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $2.91M 10-Q · filed 2024-08-09 | $2.51M derived: sum of 3 quarters · filed 2025-02-28 | -$2.52M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $1.67M 10-Q · filed 2024-05-08 | $1.26M derived: sum of 2 quarters · filed 2025-02-28 | -$3.76M derived: sum of 3 quarters · filed 2025-02-28 | -$1.39M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$407.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$5.44M derived: sum of 2 quarters · filed 2025-02-28 | -$3.06M derived: sum of 3 quarters · filed 2025-02-28 | $2.07M 10-K · filed 2025-02-28 |
| 2022-09-30 | -$5.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$2.65M derived: sum of 2 quarters · filed 2023-11-09 | $2.48M 10-Q · filed 2023-11-09 | $4.11M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $2.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $7.51M 10-Q · filed 2023-08-08 | $9.14M derived: sum of 3 quarters · filed 2024-03-14 | $9.06M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $5.13M 10-Q · filed 2023-05-09 | $6.76M derived: sum of 2 quarters · filed 2024-03-14 | $6.69M derived: sum of 3 quarters · filed 2024-03-14 | -$483.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.56M derived: sum of 2 quarters · filed 2024-03-14 | -$5.62M derived: sum of 3 quarters · filed 2024-03-14 | -$2.35M 10-K · filed 2024-03-14 |
| 2021-09-30 | -$75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$7.25M derived: sum of 2 quarters · filed 2022-11-07 | -$3.99M 10-Q · filed 2022-11-07 | -$3.94M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | -$7.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$3.91M 10-Q · filed 2022-08-08 | -$3.87M derived: sum of 3 quarters · filed 2023-03-03 | -$2.13M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $3.26M 10-Q · filed 2022-05-06 | $3.31M derived: sum of 2 quarters · filed 2023-03-03 | $5.04M derived: sum of 3 quarters · filed 2023-03-03 | $1.21M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $1.78M derived: sum of 2 quarters · filed 2023-03-03 | -$2.05M derived: sum of 3 quarters · filed 2023-03-03 | $1.65M 10-K · filed 2023-03-03 |
| 2020-09-30 | $1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$2.09M derived: sum of 2 quarters · filed 2021-11-08 | $1.60M 10-Q · filed 2021-11-08 | $6.80M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$3.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$139.00K 10-Q · filed 2021-08-09 | $5.06M derived: sum of 3 quarters · filed 2022-03-01 | $2.86M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $3.69M 10-Q · filed 2021-05-07 | $8.90M derived: sum of 2 quarters · filed 2022-03-01 | $6.70M derived: sum of 3 quarters · filed 2022-03-01 | $8.27M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $5.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $3.00M derived: sum of 2 quarters · filed 2022-03-01 | $4.57M derived: sum of 3 quarters · filed 2022-03-01 | $5.23M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$631.00K derived: sum of 2 quarters · filed 2020-11-06 | $25.00K 10-Q · filed 2020-11-06 | $37.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.23M 10-Q · filed 2020-08-06 | $2.24M derived: sum of 3 quarters · filed 2021-03-01 | $1.47M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $656.00K 10-Q · filed 2020-05-11 | $668.00K derived: sum of 2 quarters · filed 2021-03-01 | -$101.00K derived: sum of 3 quarters · filed 2021-03-01 | -$2.92M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$757.00K derived: sum of 2 quarters · filed 2021-03-01 | -$3.57M derived: sum of 3 quarters · filed 2021-03-01 | -$14.11M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$769.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$3.58M derived: sum of 2 quarters · filed 2019-11-07 | -$14.13M 10-Q · filed 2019-11-07 | -$11.93M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$13.36M 10-Q · filed 2019-08-05 | -$11.16M derived: sum of 3 quarters · filed 2020-03-02 | -$16.21M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$10.54M 10-Q · filed 2019-05-09 | -$8.34M derived: sum of 2 quarters · filed 2020-03-02 | -$13.40M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$2.85M derived: sum of 2 quarters · filed 2020-03-02 | $8.21M 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$5.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $6.01M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $11.06M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $4.30M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |